(112) Profile of Antiplatelet Use in Patients After Myocardial Infarction in a General Hospital in Banjarmasin During 2016-2020

Sunday, August 28, 2022

8:00 AM – 1:45 PM CEST

Location: Hall C

Publication Number: 1157

Presenting Author(s)

Pandji Winata Nurikhwan
– dr., School of Medicine Lambung Mangkurat University, Banjarmasin, Kalimantan Selatan, Indonesia

Co-Author(s)

Muhammad Nur Mahmudi
– School of Medicine Lambung Mangkurat University, Indonesia
Alfi Yasmina
– School of Medicine Lambung Mangkurat University, Banjarmasin, Kalimantan Selatan, Indonesia
Djallalluddin Djallalluddin
– Department of Internal Medicine, Faculty of Medicine, Universitas Lambung Mangkurat, Indonesia
Dwi Laksono Adiputro
– Department of Cardiology, Faculty of Medicine, Universitas Lambung Mangkurat, Indonesia

Background: Antiplatelet drugs are the first line in the treatment of myocardial infarction. The use of antiplatelets after myocardial infarction can be influenced by various factors.

Objectives: This study aimed to determine the profile of antiplatelet drugs use in post-myocardial infarction patients in a genreal hospital in Banjarmasin during 2016-2020, as a whole and based on age, gender, bleeding history, and atrial fibrillation history.

Methods: The design of this drug utilization study was descriptive, conducted on medical record data of patients with myocardial infarction in a general hospital in Banjarmasin during 2016-2020. The data collected were the post-myocardial infarction antiplatelet use during hospitalization, which was analyzed descriptively based on antiplatelet types, age, gender, bleeding history, and atrial fibrillation history.

Results: A total of 887 myocardial infarction patients were included, aged mostly under 75 years old (94.8%), mostly were males (77.3%), and only 0.8% and 0.7% of the patients had a history of major bleeding and atrial fibrillation, respectively. Among the 887 myocardial infarction patients, the proportion of antiplatelet use during 2016-2020 ranged between 86.9-94.7%, without major changes from year to year. Based on age, the use of antiplatelets was tend to be higher in patients aged < 75 years compared to those aged ≥ 75 years (89.88% vs 81.34%). Based on gender, there was no considerable difference in antiplatelet use between females and males (90.5% vs 89.42%). Meanwhile, based on the history of bleeding and atrial fibrillation, there was no differences in the use of antiplatelet agents.

Conclusions: It can be concluded that the use of antiplatelets in post-myocardial infarction patients in a general hospital in Banjarmasin was mostly in accordance with the treatment guidelines for myocardial infarction, and younger patients tended to have higher proportion in antiplatelet use.